CasNo.943319-70-8,Ponatinib,(943319-70-8) Suppliers

0 Metric Ton	Negotiable

Min.Order :0 Metric Ton
Purity: 98% min

Keywords

Ponatinib AP 24534; AP24534; AP-24534 943319-70-8

Quick Details

Appearance:
Application:Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively. IC50 value: 0.37 nM/1.1 nM/1
PackAge:10mg;50mg;100mg
ProductionCapacity:50-100|Metric Ton|Day
Storage:-20℃
Transportation:

Superiority:

AP24534

PonatinibPonatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively. IC50 value: 0.37 nM/1.1 nM/1.5 nM/2.2 nM/5.4 nM (Abl/PDGFRα/VEGFR2/FGFR1/Src) [1] Target: Abl; multikinase in vitro: AP24534 potently inhibits native Abl, AblT315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM.

url：www.medchemexpress.cn/ponatinib.html

Details:

AP24534

PonatinibPonatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively. IC50 value: 0.37 nM/1.1 nM/1.5 nM/2.2 nM/5.4 nM (Abl/PDGFRα/VEGFR2/FGFR1/Src) [1] Target: Abl; multikinase in vitro: AP24534 potently inhibits native Abl, AblT315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM.

url：www.medchemexpress.cn/ponatinib.html